Status:
RECRUITING
Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Conditions:
Transplant-Related Disorder
Eligibility:
All Genders
16+ years
Phase:
NA
Brief Summary
To assess the effectiveness of interventions including health monitoring and regular return follow-up reminders for patients with a high Composite Immune Risk Score.
Detailed Description
This study aims to prospectively evaluate the effectiveness of the Composite Immune Risk Score in real-world clinical setting.
Eligibility Criteria
Inclusion
- 1\) Patients must be ≥ 16 years of age;
- 2\) Patients receiving haploidentical allo-HSCT;
- 3\) Patients have to sign an informed consent form before the start of the research procedure.
Exclusion
- 1\) Tandem transplantation or multiple transplantations;
- 2\) Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements;
- 3\) Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.
Key Trial Info
Start Date :
February 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2028
Estimated Enrollment :
456 Patients enrolled
Trial Details
Trial ID
NCT06208137
Start Date
February 29 2024
End Date
April 1 2028
Last Update
August 13 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China, 300020